ATA Guidelines Tools

Adults with Differentiated THyroid Cancer - 2025 Update

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1540959

Contents of this Issue

Navigation

Page 34 of 49

35 Table 10. Summary of Recommendations for Initial RAI Following Thyroidectomy a Risk category Typical RAI recommendation Recommended 131 I activity level Goals of therapy Low No 1.1–1.85 GBq (30–50 mCi) None or remnant ablation Intermediate-low and intermediate-high Consider 1.1–3.7 GBq (30–100 mCi) Remnant ablation +/– adjuvant therapy High Yes 3.7–5.55 GBq (100–150 mCi) Remnant ablation and adjuvant therapy Distant metastases Yes 3.7–7.4 GBq (100–200 mCi) or consider dosimetry Treatment of known disease, remnant ablation a Note that these recommendations represent guidelines, and that a variety of additional features including patient preference, comorbid conditions, access to care, pre-therapy imaging, and others may influence the decision to treat with RAI as well as the resulting activity level. Consistent with the Martinique documents, the final recommendation for administered activity should be based on multidisciplinary management recommendations. Table 11. Low-risk DTC With Excellent Response to Therapy De-escalation Recommendations Treatment and response to therapy Unstimulated thyroglobulin TSH Suggested frequency of neck ultrasound Hemithyroidectomy Once post-operatively (See Rec 48) Normal a Every 1–3 years for 5–8 years Total thyroidectomy, no RAI Excellent response <2.5 ng/mL with undetectable TgAb Normal Every 1–3 years for 5–8 years, then discontinue unless Tg level rises or TgAb becomes newly detectable Total thyroidectomy + RAI Excellent response <0.2 ng/mL with undetectable TgAb Normal Every 1–3 years for 5–8 years and then discontinue unless Tg level rises or TgAb becomes newly detectable Recommendations on ultrasound monitoring in low-risk patients aer total thyroidectomy with excellent biochemical response and no suspicious features on imaging. Imaging is indicated in patients with rising thyroglobulin (Tg ), new development of anti-thyroglobulin antibodies (TgAb), concerning physical exam, or symptoms. Type and location of imaging depends on the histological type of thyroid cancer and other patholog y features. Use of Tg levels following hemithyroidectomy, and use of neck ultrasound in patients with FTC and OTC require further study. a Assuming no nodules in residual lobe requiring monitoring as per ATA thyroid nodule guidelines.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Adults with Differentiated THyroid Cancer - 2025 Update